<DOC>
	<DOC>NCT00928681</DOC>
	<brief_summary>study to investigate the safety and efficacy properties of PF-00547659 in patients with active ulcerative colitis</brief_summary>
	<brief_title>A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>A positive histological diagnosis of UC ≥3 months prior to entry into the study. If a histological diagnosis is not available but all signs and symptoms suggest UC, the subject's eligibility should be discussed with Pfizer. Active UC as defined by a score of ≥6 on the Mayo score. An endoscopic (by flexible sigmoidoscopy) subscore of ≥2 on the Mayo score determined within 7 days of first dosing. Subjects with UC, which is confined to a proctitis on a flexible sigmoidoscopy. Subjects who have had surgery as a treatment for UC or are likely to require surgery within the duration of the study. Subjects displaying clinical signs of ischemic colitis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>